TMFBiologyFool

Brian Orelli

Somewhere between his graduate thesis on BRCA1, a gene that causes hereditary breast cancer, and his postdoctoral fellowship in DNA repair, Brian realized he enjoyed analyzing other people's data more than running his own experiments. Having gotten his first taste of how to analyze stocks from The Motley Fool many years prior, it was only fitting that he came full circle and started writing about biotech, pharmaceutical, and medical device companies for Fool.com. He also covers the health insurance industry to keep from going into binary-event overload. When not writing at The Motley Fool or trade journals like Nature Biotechnology and BioWorld, Brian can be found coaching soccer or hanging out at the beach in his hometown of San Diego.

TMFBiologyFool’s Activity

Wed Nov 26

NL

Article

TMFBiologyFool published an article 8:15 AM

Will Insulin Pricing Be MannKind Corporation's Downfall?

MannKind marketing partner Sanofi had to discount its Lantus insulin to get insurers to cover the drug.

Thu Nov 20

NL

Article

TMFBiologyFool published an article 12:42 PM

Gilead Sciences Inc. Just Paid $125 Million for Something It Can't Use for a Year

Gilead's newly acquired priority review voucher is useful, but requires the biotech to give the FDA a 365-day warning that it's going to use the voucher.

Tue Nov 18

NL

Article

TMFBiologyFool published an article 4:00 PM

Merck IMPROVEs-IT Causing These Biotechs' Stock Prices to Improve Too

Thanks to Merck, Regeneron Pharmaceuticals and Esperion Therapeutics likely won't have to run outcomes studies on their cholesterol drugs.

Mon Nov 17

NL

Article

TMFBiologyFool published an article 1:50 PM

For This Obesity Drug, Europe Trumps the U.S.

Europe is key for Orexigen's Contrave. Shares jumped despite problems with the U.S. launch.

Mon Nov 10

NL

Article

TMFBiologyFool published an article 2:17 PM

Gilead Sciences Inc. Breathes a Sigh of Relief -- Hepatitis C Patients, Not So Much

Merck's new hepatitis C combination doesn't work all that well for short durations. Gilead Sciences' Harvoni is safe for now.

Fri Nov 7

Rule Breakers article.

TMFBiologyFool published an update. 4:58 PM

NL

Article

TMFBiologyFool published an article 2:29 PM

Isis Pharmaceuticals Inc. Strikes Out on Its Own

Isis Pharmaceuticals uses its third-quarter earnings call to announce a reorganization as it pushes into late-stage development on its own.

Rule Breakers article.

TMFBiologyFool published an update. 9:06 AM

Thu Nov 6

Rule Breakers article.

TMFBiologyFool published an update. 9:33 PM

NL

Article

TMFBiologyFool published an article 8:13 PM

Emergent BioSolutions Inc Busts Through Guidance. Sort of.

Emergent BioSolutions' upfront payment from its deal with MorphoSys caused a large increase in revenue in the third quarter.

NL

Article

TMFBiologyFool published an article 4:27 PM

5 Things Biogen Idec Inc's Management Wants You to Know

Biogen Idec's multiple sclerosis and hemophilia pipelines are progressing.

NL

Article

TMFBiologyFool published an article 3:17 PM

All Eyes on ISIS Pharmaceuticals, Inc.'s Pipeline

Isis has an approved drug, but earnings should be all about the pipeline of 32 drugs.

Rule Breakers article.

TMFBiologyFool published an update. 10:00 AM

Wed Nov 5

NL

Article

TMFBiologyFool published an article 7:41 PM

Alnylam Pharmaceuticals, Inc. Has This Ratio Right

Alnylam's third-quarter earnings call was all about the pipeline data.

Rule Breakers article.

TMFBiologyFool published an update. 3:08 PM

Hidden Gems article.

TMFBiologyFool published an update. 3:04 PM

Rule Breakers article.

TMFBiologyFool published an update. 1:53 PM

NL

Article

TMFBiologyFool published an article 12:50 PM

Momenta Pharmaceuticals, Inc. Pushes Forward

With just $4.7 million from sales of enoxaparin in the third quarter, investors have to be focused on the pipeline.

Rule Breakers article.

TMFBiologyFool published an update. 10:00 AM

Tue Nov 4

NL

Article

TMFBiologyFool published an article 11:50 PM

Genomic Health, Inc.'s Lumpy Growth

Revenue and test volume growth come back to earth, but investors should focus on the quarters ahead.

Show More Activity ...

CAPS Stats & Trivia

CAPS Player Rating 95.88
Player Rank 3097 out of 75068
Score 1232.31
Score Change Today +2.65
Accuracy 66.35%
Active Picks 73
Total Picks 213
Best Pick MYL (+328.23)
Worst Pick INCY (-680.69)
Average Score per Pick 5.79
Charms Earned 10
Highest Rated Favorite zzlangerhans
Go to TMFBiologyFool’s CAPS page

Boards Stats & Trivia

Three stars, 500 posts CAPS All Star
Board Posts 928
Recs Received 982
People who have rec'd these posts 380
Recs to Posts Ratio (last 30 days) N/A
Threads Started 90
Threads Started Percentage 9.70 %
Most Frequent Board Buying or Selling a Home
Very First Post Re: How many is enough? (6/6/2001)
Percentage of Posts Rec'd 48.17 %
Show TMFBiologyFool’s 10 Latest Posts